Developing a novel class of cancer therapeutics for solid tumors.

Resolute is developing a novel class of therapeutics for aggressive, difficult-to-treat, and rare solid tumors.

Established with a mission to cure solid tumors, we leverage our MAC-TACs (Macrophage Targeted Conjugates) technology platform to design a broad range of biomarker-driven, first-in-class, pan-cancer, synthetic molecules with the potential to deliver superior safety and efficacy over existing standard of care.  Our team shares a common vision of advancing science to improve the lives of cancer patients worldwide. Our deep understanding of solid tumor biology allowed us to develop a completely novel class of therapeutics. 

Our MAC-TAC platform technology harnesses the power of Tumor-Associated Macrophages (TAMs), employing them to rapidly and efficiently deliver cytotoxic payloads to tumors. This strategy may overcome cancer recurrence and evolved resistance associated with direct targeting of cancer cells. 

MAC-TACs offer a promising solution to treating cancer.

Established with a mission to revolutionize the field of oncology, we are committed to providing a novel and effective tumor-agnostic therapeutic platform. Our understanding of solid tumor biology allowed us to develop a universal drug-delivery platform for treating solid tumors. Our MAC-TAC design bypasses the complications associated with tumor heterogeneity and minimizes the risk of drug resistance and recurrence, offering a promising solution in the fight against malignancies.